Results 111 to 120 of about 512,862 (249)
KMT2A degradation is observed in decitabine‐responsive acute lymphoblastic leukemia cells
Molecular Oncology, EarlyView.We demonstrate that decitabine (DEC) not only degrades the DNA methyltransferase DNMT1 but also the leukemic driver lysine methyltransferase KMT2A likely due to structural similarity of the DNA‐binding CXXC domains. DEC influences KMT2A downstream processes and synergizes with menin inhibitor revumenib (REV) to decrease leukemic cell proliferation, and
Luisa Brock +10 more
wiley +1 more source
Molecular Oncology, EarlyView.CD226+CD8+ T cells express elevated levels of RUNX2, exhibit higher proliferation capacity, cytokines and cytolytic molecules expression, and migratory capacity. In contrast, CD226−CD8+ T cells display an exhausted phenotype associated with the increased expression of co‐inhibitory receptors and impaired effector functions.
Maryam Rezaeifar +4 more
wiley +1 more source
Eclipsing binaries in open clusters. III. V621 Per in chi Persei
, 2004 V621 Persei is a detached eclipsing binary in the open cluster chi Persei which is composed of an early B-type giant star and a main sequence secondary component.
Andersen +54 more
core +2 more sources
Molecular Oncology, EarlyView.Triacsin C inhibition of the acyl‐CoA synthetase long chain (ACSL) family decreases multiple myeloma cell survival, proliferation, mitochondrial respiration, and membrane potential. Made with Biorender.com. Multiple myeloma (MM) is an incurable cancer of plasma cells with a 5‐year survival rate of 59%.
Connor S. Murphy +12 more
wiley +1 more source
Internal Structure of Addition Chains: Well-Ordering [PDF]
, 2015 An addition chain for $n$ is defined to be a sequence $(a_0,a_1,\ldots,a_r)$ such that $a_0=1$, $a_r=n$, and, for any $1\le k\le r$, there exist $0\le i ...
Altman, Harry
core
Molecular Oncology, EarlyView.FOXL2 c.402C>G mutation drives granulosa cell tumors. Using CRISPR technology, we selectively corrected this mutation, reducing malignancy and increasing sensitivity to dasatinib and ketoconazole. Transcriptomic changes revealed potential therapeutic targets, demonstrating CRISPR's promise for treating this rare ovarian cancer.
Sandra Amarilla‐Quintana +17 more
wiley +1 more source
Molecular Oncology, EarlyView.Prostate cancer is a leading malignancy with significant clinical heterogeneity in men. An 11‐gene signature derived from dysregulated epithelial cell markers effectively predicted biochemical recurrence‐free survival in patients who underwent radical surgery or radiotherapy.
Zhuofan Mou, Lorna W. Harries
wiley +1 more source
Primary extranodal diffuse large B‐cell lymphoma: Molecular features, treatment, and prognosis
Aging and Cancer, Volume 3, Issue 3-4, Page 133-146, September-December 2022., 2022 One‐third of DLBCL arises from extranodal organs and is challenging to manage. Molecular features are critical to elucidate the differences in clinical features, predict the disease prognosis, and improve effective targeted therapeutic strategies. Abstract Diffuse large B‐cell lymphoma (DLBCL) is the most common subtype of non‐Hodgkin's lymphoma and ...
Si‐Yuan Chen +3 more
wiley +1 more source
We present spectroscopy of three hydrogen-deficient central stars of faint planetary nebulae, with effective temperatures ($T_\mathrm{eff}$) in excess of 100,000 K.
Bond, Howard E. +3 more
core +1 more source
Clinical significance of stratifying prostate cancer patients through specific circulating genes
Molecular Oncology, EarlyView.We tested a specific panel of genes representative of luminal, neuroendocrine and stem‐like cells in the blood of prostate cancer patients, showing predictive value from diagnosis to late stages of disease. This approach allows monitoring of treatment responses and outcomes at specific time points in trajectories.
Seta Derderian +12 more
wiley +1 more source